---
title: 'The Future of Follicular Lymphoma Management: Strategies on the Horizon'
date: '2025-02-28'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/40019447/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20250228170956&v=2.18.0.post9+e462414
source: Blood
description: Progress in the therapy of follicular lymphoma (FL), the most common
  indolent lymphoma subtype, has been achieved in recent years with significant improvement
  in median overall survival. Most patients diagnosed with FL will now die from other
  causes. Multiple novel immunotherapy and other targeted therapies are now approved
  for relapsed and refractory disease. However, early progression and transformation
  to aggressive lymphoma remain key issues requiring further innovation. We expect
  ...
disable_comments: true
---
Progress in the therapy of follicular lymphoma (FL), the most common indolent lymphoma subtype, has been achieved in recent years with significant improvement in median overall survival. Most patients diagnosed with FL will now die from other causes. Multiple novel immunotherapy and other targeted therapies are now approved for relapsed and refractory disease. However, early progression and transformation to aggressive lymphoma remain key issues requiring further innovation. We expect ...